This week on Pharm5:

• Amazon’s RxPass Subscription


• Brenzavy (bexagliflozin) for T2DM


• Leqimbi (lecanemab) for mild Alzheimer disease


• Vaccine efficacy for Omicron XBB


• TidePool Loop app cleared by FDA

Connect with us!

• Listen to our podcast: Pharm5


• Follow us on Twitter: @LizHearnPharmD

References:

1. Gupta V. Introducing RxPass from Amazon Pharmacy, a $5 prescription subscription that helps prime members who take multiple medications save time and money. US About Amazon. http://bit.ly/3ReGKhE. Published January 24, 2023. Accessed January 26, 2023.


2. All RxPass medications. http://bit.ly/3kN8628. Accessed January 27, 2023.


3. FDA grants accelerated approval for Alzheimer's disease treatment. U.S. Food and Drug Administration. http://bit.ly/3HxSkRI. Accessed January 26, 2023.


4. Lecanemab. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. http://bit.ly/3DeqR4X. Accessed January 26, 2023.


5. Park B. Brenzavvy approved for adults with type 2 diabetes. MPR. http://bit.ly/3DjPME3. Published January 23, 2023. Accessed January 26, 2023.


6. Early estimates of bivalent mrna booster dose vaccine effectiveness in preventing symptomatic SARS-COV-2 infection attributable to omicron ba.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022–January 2023. Centers for Disease Control and Prevention. https://bit.ly/3kRkMos. Published January 25, 2023. Accessed January 26, 2023.


7. NCIRD Surveillance Systems. Centers for Disease Control and Prevention. https://bit.ly/3wzcfti.  Published January 17, 2023. Accessed January 26, 2023.


8. Groundbreaking: Tidepool Loop receives FDA clearance. Tidepool. http://bit.ly/3kFRtoR. Accessed January 26, 2023.


9. Briskin A. Tidepool Loop cleared by FDA. diaTribe. https://bit.ly/3XH2mFL. Published January 26, 2023. Accessed January 26, 2023.